Reflex Epilepsy, PhotosensitivePPRsNCT04076410
Efficacy of Lenses in Abolishing Photoparoxysmal Responses
A study testing Z1 lens, Experimental Lens 1 and Experimental Lens 2 in people with Reflex Epilepsy, Photosensitive and Eyeglasses, run by Aston University at 2 sites in United Kingdom.
Trial summary
Background. Blue lenses that filter out red light have been proposed as a new therapeutic alternative for patients with PSE, such as the lens Zeiss Clarlet Z1. This lens only allows a small overall quantity of visible light, and particularly a minimum percentage of red light, to pass through. Read more about this study
- Who is it for?
- Ages 5 to 18 years
- Conditions the study is for
- Reflex Epilepsy, Photosensitive, Eyeglasses
- What is being tested?
- Z1 lens, Experimental Lens 1 and Experimental Lens 2
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 28 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 20 Feb 2021to 31 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
- Inclusion Criteria:
- Children and adolescents between 5-18 years with suspected or confirmed diagnosis of photosensitive epilepsy (PSE), whether they are taking antiepileptic medication or not.
- Capacity to:
- maintain concentration during the procedure
- follow simple commands
- assent (under 16 years) or consent (16-18 years) to participate after understanding the purpose of the study.
- Exclusion Criteria:
- Presence of a condition that may compromise the ability to tolerate the procedure and/or the capacity to assent or consent, such as:
- intellectual disability
- attention-deficit/hyperactivity disorder
- autism spectrum disorders
- difficulties to understand verbal/written explanations in English
- Refusal to participate
- Generalized seizure during the EEG procedure.
- Female patients suspected or known to be pregnant.
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, West Midlands, B4 6NH
Aston University
Birmingham, West Midlands, B4 7ET
About this study
Official title: Efficacy of New Lenses in Abolishing Photoparoxysmal Responses in Paediatric Patients With Photosensitive Epilepsy (PSE)
Background. Blue lenses that filter out red light have been proposed as a new therapeutic alternative for patients with PSE, such as the lens Zeiss Clarlet Z1. This lens only allows a small overall quantity of visible light, and particularly a minimum percentage of red light, to pass through. However, these characteristics entail two main pitfalls: reduced applicability in high- latitude regions and lack of transmission for the red and yellow colors. The latter would mainly expose patients to the other colors that compose the visible light, and particularly to the blue visible light. This exposure might be damaging for their eyes in the long term, as it has been reported in some studies.
Aim. To determine whether four new lenses with different spectral characteristics are not inferior in efficacy to Z1 to reduce the PPRs in patients with PSE.
Read more
Participants. Patients between 5-18 years with suspected or confirmed PSE, referred to the Neurophysiology Service at Birmingham Children's Hospital (BCH) for an EEG with IPS/pattern stimulation.
Objectives \& Outcomes:
1.A) Primary Objective: To evaluate the reduction/suppression produced by four new lenses in the PPRs shown by patients with PSE during an EEG with IPS/pattern stimulation, and compare it with the reduction provoked by the Z1 lens in the same individuals.
- B) Primary Outcome: reduction/suppression in both the PPR and the standardized photoparoxysmal response range (SPR) for IPS and pattern stimulation.
- A) Secondary Objectives:
- To obtain feedback from the patients who acquire a pair of our lenses regarding tolerability, overall adherence to treatment and improvement in the quality of life.
- Comparison of the reduction/suppression in the PPRs between our lenses and the Z1 lens in those retrospective patients with PSE seen between 2008-2017 at the Aston Brain Center.
2.B) Secondary Outcomes:
- Mean score obtained in adherence to treatment, tolerability, reduction in seizure frequency and autonomy according to the patient/parents or carers satisfaction questionnaires.
- Reduction/suppression in both the PPR and the standardized photoparoxysmal response range (SPR) for IPS and pattern stimulation in those patients recruited at the Aston Brain Center.
Read the detailed description
- BACKGROUND Photosensitive epilepsy (PSE) is the most common of reflex epilepsies and represents approximately 10% of all new cases of epilepsy in the age range 7-19 years (Harding \& Jeavons, 1994). Photosensitivity is the nuclear feature of PSE, in which seizures are provoked by light stimuli or visual patterns, such as lines, gratings or checkerboards (Yalçin, Kaymaz, \& Forta, 2000)(Fisher, Harding, Erba, Barkley, \& Wilkins, 2005). Therefore, usual external triggers of seizures in the daily life of patients with PSE are sunlight and screens, like televisions (TVs), video games and computer displays. Photic/pattern sensitivity can be detected on the electroencephalogram (EEG) by the presence of a specific abnormality, called the 'photoparoxysmal response' (PPR), which is usually evoked by intermittent photic stimulation (IPS) or pattern stimulation, respectively (Quirk et al., 1995). Red color (wavelength around 600-700nm) has been proposed to be the most provocative stimulus among the primary colors to trigger photosensitivity/pattern-sensitivity in these patients (Fisher et al., 2005)(Guerrini \& Genton, 2004). There are certain preventive measures to avoid triggering external stimuli which are particularly useful in PSE patients, but pharmacological treatment is required when seizures are not controlled by preventive measures or when photic or pattern-induced seizures coexist with spontaneous seizures. However, adverse effects of antiepileptic drugs (AEDs) and the relapse percentage after medication withdrawal, which may be nearly 50% (Verrotti et al., 2014), drove investigators to seek other therapeutic alternatives, such as the use of blue lenses that filter out red light. To date, the most extensively investigated lens has been Zeiss Clarlet Z1, which abolished PPRs in 75.9% of 610 patients (Giuseppe Capovilla et al., 2006). This effect was accounted for by the spectroscopic profile of Z1, that shows the minimal transmittance for the spectrum of red color (600-700 nm) (G Capovilla et al., 1999) and a luminous transmittance for the visible spectrum (τν) around 7%. However, Z1 transmittance characteristics have two main limitations for its use in everyday life: 1) it is a very dark lens and not practical in high-latitude regions, where the number of sunlight hours is reduced; 2) its lack of transmission in the red and yellow parts of the spectrum determines that people using Z1 are almost completely exposed to blue visible light, which has been associated with the appearance of ophthalmological diseases in the long term, such as age-related macular degeneration (AMD) ("blue-light hazard" phenomenon) (Mainster, 2006).
- RATIONALE In light of these limitations, we hypothesized that a new type of lenses created by improving some spectral characteristics of Z1 could also be helpful for patients with PSE. This is the reason why we have designed four new lenses at the Aston Brain Center (ABC, Aston University) in collaboration with the Aston University Vision Sciences Department. These new lenses were firstly tested in those patients with PSE referred to the ABC between 2008-2017, when this center was the referral site in West Midlands to perform an EEG with photic/pattern stimulation. To date, no lens has demonstrated similar efficacy to Z1 with improved transmittance characteristics. Our new lenses may become an alternative or adjuvant therapy for paediatric and adult patients with PSE, leading to a reduction in the necessary dose of medication, with consequently less probability of adverse effects and an overall improvement in the quality of life.
- AIM AND OBJECTIVES
The aim of our study is to demonstrate that our lenses are not inferior in efficacy to reduce the PPRs in comparison with Z1 in a sample of children and adolescents with PSE.
- The primary objective of this study is to investigate the efficacy of these four lenses in suppressing the PPRs evoked by IPS and/or pattern stimulation in a sample of pediatric patients with PSE recruited at the Birmingham Women's and Children's NHS Foundation Trust (BWCH), and compare their results with those obtained with Z1 in the same patient.
- Our secondary objectives are:
- To collect the retrospective information (clinical and EEG data) of those PSE patients who were seen between 2008 and 2017 at the ABC, where the lenses were firstly tested before moving the equipment to the BWCH.
- To obtain feedback from the patients who finally acquire a pair of our lenses in relation to the overall adherence to treatment, tolerability and improvement in the quality of life. To achieve this objective, we will send a patient satisfaction questionnaire (PSQ) to these patients approximately 6 months after purchasing the lenses.
- DESIGN
This is a single-arm clinical trial. We will carry out two types of study: a prospective (forward) study recruiting patients at BWCH and also a retrospective (backwards) study collecting those patients seen at the ABC between 2008 and 2017. In both studies, data analysis will take place at Aston University after being pseudonymized.
- METHODS
5.1. Recruitment
Prospective study (BWCH, Aston University):
Patients (either males or females) from 5 to 18 years with suspected or confirmed diagnosis of generalised epilepsy with photosensitivity or photosensitive epilepsy (PSE) who are referred to the Neurophysiology Service at BCH for an EEG with IPS/pattern stimulation to confirm the diagnosis or check evolution, whether they are taking AEDs or not. Participants will be able to maintain concentration during the procedure, follow simple commands given by the NHS PI and have the capacity to assent (under 16 years) or consent (16-18 years) to participate after checking that they have understood the purpose of the study.
Retrospective study (Aston University):
•Selection criteria followed in the retrospective study conducted at the ABC were the same, except for the age criterion, since adult patients were also seen at the ABC.
5.2. Trial Procedures
Prospective study (BWCH, Aston University):
- On the first visit to the BWCH, a standardised procedure for EEG with IPS (Kasteleijn-Nolst Trenité et al., 2012) will be performed, followed by stimulation with visual patterns (stationary vertical grids at different spatial frequencies on a screen). If PPRs are shown in response to IPS/pattern stimulation, lenses will be tested to evaluate the relative reduction produced by our lenses \& Z1 on the PPRs evoked by IPS/pattern testing. This reduction will be determined by the change in both the type of PPR and the standardized photoparoxysmal response range (SPR).
- If our lenses are effective and patients/families decide to acquire one of them, they will be asked to fill in a Likert-scale PSQ approximately 6 months after purchasing the lenses. This information will provide us with some feedback on the overall adherence to treatment, tolerability and improvement in the quality of life.
5.2.2) Retrospective study (Aston University): it will consist in the same procedures as the prospective study, but in this case the PSQ was not sent to patients/families.
- DATA ANALYSIS
A minimum sample size of 76 patients was obtained based upon data collected from a previous pilot study, taking into consideration a power value of 80%, an alpha value of 5% and a non-inferiority margin of 0.03.
For each patient, we will compare the reduction/suppression on both the PPR and the SPR between the different lenses (α=0.05). PSQ results will be expressed by the percentages of patients/parents who marked a particular response in these multiple-choice questionnaires.
Missed data (patients who finally drop out of the study) will not be considered for analysis purposes.
- ETHICAL CONSIDERATIONS
All procedures conducted will comply with the Declaration of Helsinki as revised in 2013, the Data Protection Act 1998 and Local Information Governance protocols. Consent will be sought from parents/legal guardians and patients over 15 years, as well as assent in the case of younger patients.
Only pseudonymized raw data will be available for sharing outside of the department as the analysis is to be performed by the PI-based at the sponsor site (Aston University). Data storage will be in keeping with the Trust Information Governance policies.
- Conditions
- Reflex Epilepsy, Photosensitive, Eyeglasses
- Being tested
- Z1 lens, Experimental Lens 1, Experimental Lens 2, Experimental Lens 3, Experimental Lens 4
- Keywords
- photosensitivity, pattern sensitivity, Electroencephalography, Photic Stimulation, Pattern Stimulation, photoparoxysmal response, Light, Visible, Red Colour, Blue Light, children, epilepsy, standardized photoparoxysmal response range
- Medical subject headings
- Epilepsy, Reflex, Photosensitivity Disorders, Erythema, Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Z1 lensDevice
Also called Zeiss F133
CE marked device
Experimental Lens 1Device
CE marked device
Experimental Lens 2Device
CE marked device
Experimental Lens 3Device
CE marked device
Experimental Lens 4Device
CE marked device
| Study group | Role | What they receive |
|---|---|---|
| 5 Lenses | Experimental | The five lenses will be tested in each patient following always the same specific order, with the most protective lenses tested first (Z1).
Z1F133 (Zeiss Clarlet Z1) is a CE marked device manufactured by Carl Zeiss Vision International GmBH (Aalen, Germany).
Our lenses are CE marked devices manufactured by Cerium Optical Products (Kent, UK). Receives: Device: Z1 lens; Device: Experimental Lens 1; Device: Experimental Lens 2; Device: Experimental Lens 3; Device: Experimental Lens 4 |
What is being measured
The primary outcome is the main question the study is designed to answer.
PPR change
Relative change in the photoparoxysmal response grade
Measured: Baseline (First visit T0)
SPR change
Relative change in the standardized photoparoxysmal response range (SPR)
Measured: Baseline (First visit T0)
Secondary outcomes (1)
Adherence and tolerability to lenses in everyday life
The score obtained in the different sections of the Patient Satisfaction Questionnaire [on a scale from 1 (worst outcome) to 5 (best outcome)]
Measured: 6 months after acquiring the lenses (T6)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2019
- Study start20 Feb 2021
- Primary completion4 Jun 2024
- Study completion31 Jan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Reflex Epilepsy, PhotosensitiveStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Participants will be recruited among those patients (both males and females) from 5 to 18 years with suspected or confirmed diagnosis of generalised epilepsy with photosensitivity or photosensitive epilepsy (PSE) who comply with the established inclusion criteria. No control patients will be required, since each patient will be tested with the different lenses in a specific order and will be, in turn, his/her own control. No randomisation will be carried out in our study.
- Masking
- None (open label)
- Enrolment
- 28 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aston University
- Sponsor type
- University, hospital or other
- Collaborators
- Birmingham Women's and Children's NHS Foundation Trust
- Responsible party
- Principal investigator, Ana Checa-Ros, MD, PhD, Aston University
- Investigators
- Bryony Carr, BSc, Principal investigator, Birmingham Women's and Children's NHS Foundation TrustAna Checa-Ros, MD, PhD, Principal investigator, Aston University, Birmingham, UKSukhvir Wright, MD, PhD, Study chair, Aston University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04076410
- Sponsor's protocol ID
- 284-2019-CR
- Other IDs
- 266497, 20/EM/0030
- Acronym
- PPRs
- Status last verified
- Jun 2024
- First submitted
- 30 Aug 2019
- Last updated
- 5 Jun 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: All data recruited at BCH and at the ABC will be pseudonymized before being shared with the PI at Aston University to protect patient confidentiality.
Publications
Capovilla G, Beccaria F, Romeo A, Veggiotti P, Canger R, Paladin F. Effectiveness of a particular blue lens on photoparoxysmal response in photosensitive epileptic patients. Ital J Neurol Sci. 1999 Jun;20(3):161-6. doi: 10.1007/s100720050026.
PubMed 10541598Capovilla G, Gambardella A, Rubboli G, Beccaria F, Montagnini A, Aguglia U, Canevini MP, Casellato S, Granata T, Paladin F, Romeo A, Stranci G, Tinuper P, Veggiotti P, Avanzini G, Tassinari CA. Suppressive efficacy by a commercially available blue lens on PPR in 610 photosensitive epilepsy patients. Epilepsia. 2006 Mar;47(3):529-33. doi: 10.1111/j.1528-1167.2006.00463.x.
PubMed 16529617Fisher RS, Harding G, Erba G, Barkley GL, Wilkins A; Epilepsy Foundation of America Working Group. Photic- and pattern-induced seizures: a review for the Epilepsy Foundation of America Working Group. Epilepsia. 2005 Sep;46(9):1426-41. doi: 10.1111/j.1528-1167.2005.31405.x.
PubMed 16146439Guerrini R, Genton P. Epileptic syndromes and visually induced seizures. Epilepsia. 2004;45 Suppl 1:14-8. doi: 10.1111/j.0013-9580.2004.451011.x.
PubMed 14706039Harding, G., & Jeavons, P. (1994). Photosensitive Epilepsy: Clinics in Developmental Medicine. London, UK: McKeith Press.
Kasteleijn-Nolst Trenite D, Rubboli G, Hirsch E, Martins da Silva A, Seri S, Wilkins A, Parra J, Covanis A, Elia M, Capovilla G, Stephani U, Harding G. Methodology of photic stimulation revisited: updated European algorithm for visual stimulation in the EEG laboratory. Epilepsia. 2012 Jan;53(1):16-24. doi: 10.1111/j.1528-1167.2011.03319.x. Epub 2011 Nov 16.
PubMed 22091642Mainster MA. Violet and blue light blocking intraocular lenses: photoprotection versus photoreception. Br J Ophthalmol. 2006 Jun;90(6):784-92. doi: 10.1136/bjo.2005.086553.
PubMed 16714268Quirk JA, Fish DR, Smith SJ, Sander JW, Shorvon SD, Allen PJ. Incidence of photosensitive epilepsy: a prospective national study. Electroencephalogr Clin Neurophysiol. 1995 Oct;95(4):260-7. doi: 10.1016/0013-4694(95)00118-i.
PubMed 8529557Verrotti A, Grosso S, D'Egidio C, Parisi P, Spalice A, Pavone P, Capovilla G, Agostinelli S. Valproate in adolescents with photosensitive epilepsy with generalized tonic-clonic seizures only. Eur J Paediatr Neurol. 2014 Jan;18(1):13-8. doi: 10.1016/j.ejpn.2013.06.006. Epub 2013 Jul 26.
PubMed 23891468Yalcin AD, Kaymaz A, Forta H. Reflex occipital lobe epilepsy. Seizure. 2000 Sep;9(6):436-41. doi: 10.1053/seiz.2000.0424.
PubMed 10986003
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of New Lenses in Abolishing Photoparoxysmal Responses in Paediatric Patients With Photosensitive Epilepsy (PSE)
- ClinicalTrials.gov ID
- NCT04076410
- Acronym / sponsor ID
- PPRs / 284-2019-CR
- Conditions
- Reflex Epilepsy, Photosensitive, Eyeglasses
- Keywords
- photosensitivity, pattern sensitivity, Electroencephalography, Photic Stimulation, Pattern Stimulation, photoparoxysmal response, Light, Visible, Red Colour
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 28 participants (actual)
- Lead sponsor
- Aston UniversityUniversity, hospital or other
- Collaborators
- Birmingham Women's and Children's NHS Foundation Trust
- Study start
- 20 Feb 2021 (actual)
- Primary completion
- 4 Jun 2024 (actual)
- Study completion
- 31 Jan 2026 (estimated)
- First posted
- 3 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background. Blue lenses that filter out red light have been proposed as a new therapeutic alternative for patients with PSE, such as the lens Zeiss Clarlet Z1. This lens only allows a small overall quantity of visible light, and particularly a minimum percentage of red light, to pass through. However, these characteristics entail two main pitfalls: reduced applicability in high- latitude regions and lack of transmission for the red and yellow colors. The latter would mainly expose patients to the other colors that compose the visible light, and particularly to the blue visible light. This exposure might be damaging for their eyes in the long term, as it has been reported in some studies.
Aim. To determine whether four new lenses with different spectral characteristics are not inferior in efficacy to Z1 to reduce the PPRs in patients with PSE.
Participants. Patients between 5-18 years with suspected or confirmed PSE, referred to the Neurophysiology Service at Birmingham Children's Hospital (BCH) for an EEG with IPS/pattern stimulation.
Objectives \& Outcomes:
1.A) Primary Objective: To evaluate the reduction/suppression produced by four new lenses in the PPRs shown by patients with PSE during an EEG with IPS/pattern stimulation, and compare it with the reduction provoked by the Z1 lens in the same individuals.
- B) Primary Outcome: reduction/suppression in both the PPR and the standardized photoparoxysmal response range (SPR) for IPS and pattern stimulation.
- A) Secondary Objectives:
- To obtain feedback from the patients who acquire a pair of our lenses regarding tolerability, overall adherence to treatment and improvement in the quality of life.
- Comparison of the reduction/suppression in the PPRs between our lenses and the Z1 lens in those retrospective patients with PSE seen between 2008-2017 at the Aston Brain Center.
2.B) Secondary Outcomes:
- Mean score obtained in adherence to treatment, tolerability, reduction in seizure frequency and autonomy according to the patient/parents or carers satisfaction questionnaires.
- Reduction/suppression in both the PPR and the standardized photoparoxysmal response range (SPR) for IPS and pattern stimulation in those patients recruited at the Aston Brain Center.
Detailed description
- BACKGROUND Photosensitive epilepsy (PSE) is the most common of reflex epilepsies and represents approximately 10% of all new cases of epilepsy in the age range 7-19 years (Harding \& Jeavons, 1994). Photosensitivity is the nuclear feature of PSE, in which seizures are provoked by light stimuli or visual patterns, such as lines, gratings or checkerboards (Yalçin, Kaymaz, \& Forta, 2000)(Fisher, Harding, Erba, Barkley, \& Wilkins, 2005). Therefore, usual external triggers of seizures in the daily life of patients with PSE are sunlight and screens, like televisions (TVs), video games and computer displays. Photic/pattern sensitivity can be detected on the electroencephalogram (EEG) by the presence of a specific abnormality, called the 'photoparoxysmal response' (PPR), which is usually evoked by intermittent photic stimulation (IPS) or pattern stimulation, respectively (Quirk et al., 1995). Red color (wavelength around 600-700nm) has been proposed to be the most provocative stimulus among the primary colors to trigger photosensitivity/pattern-sensitivity in these patients (Fisher et al., 2005)(Guerrini \& Genton, 2004). There are certain preventive measures to avoid triggering external stimuli which are particularly useful in PSE patients, but pharmacological treatment is required when seizures are not controlled by preventive measures or when photic or pattern-induced seizures coexist with spontaneous seizures. However, adverse effects of antiepileptic drugs (AEDs) and the relapse percentage after medication withdrawal, which may be nearly 50% (Verrotti et al., 2014), drove investigators to seek other therapeutic alternatives, such as the use of blue lenses that filter out red light. To date, the most extensively investigated lens has been Zeiss Clarlet Z1, which abolished PPRs in 75.9% of 610 patients (Giuseppe Capovilla et al., 2006). This effect was accounted for by the spectroscopic profile of Z1, that shows the minimal transmittance for the spectrum of red color (600-700 nm) (G Capovilla et al., 1999) and a luminous transmittance for the visible spectrum (τν) around 7%. However, Z1 transmittance characteristics have two main limitations for its use in everyday life: 1) it is a very dark lens and not practical in high-latitude regions, where the number of sunlight hours is reduced; 2) its lack of transmission in the red and yellow parts of the spectrum determines that people using Z1 are almost completely exposed to blue visible light, which has been associated with the appearance of ophthalmological diseases in the long term, such as age-related macular degeneration (AMD) ("blue-light hazard" phenomenon) (Mainster, 2006).
- RATIONALE In light of these limitations, we hypothesized that a new type of lenses created by improving some spectral characteristics of Z1 could also be helpful for patients with PSE. This is the reason why we have designed four new lenses at the Aston Brain Center (ABC, Aston University) in collaboration with the Aston University Vision Sciences Department. These new lenses were firstly tested in those patients with PSE referred to the ABC between 2008-2017, when this center was the referral site in West Midlands to perform an EEG with photic/pattern stimulation. To date, no lens has demonstrated similar efficacy to Z1 with improved transmittance characteristics. Our new lenses may become an alternative or adjuvant therapy for paediatric and adult patients with PSE, leading to a reduction in the necessary dose of medication, with consequently less probability of adverse effects and an overall improvement in the quality of life.
- AIM AND OBJECTIVES
The aim of our study is to demonstrate that our lenses are not inferior in efficacy to reduce the PPRs in comparison with Z1 in a sample of children and adolescents with PSE.
- The primary objective of this study is to investigate the efficacy of these four lenses in suppressing the PPRs evoked by IPS and/or pattern stimulation in a sample of pediatric patients with PSE recruited at the Birmingham Women's and Children's NHS Foundation Trust (BWCH), and compare their results with those obtained with Z1 in the same patient.
- Our secondary objectives are:
- To collect the retrospective information (clinical and EEG data) of those PSE patients who were seen between 2008 and 2017 at the ABC, where the lenses were firstly tested before moving the equipment to the BWCH.
- To obtain feedback from the patients who finally acquire a pair of our lenses in relation to the overall adherence to treatment, tolerability and improvement in the quality of life. To achieve this objective, we will send a patient satisfaction questionnaire (PSQ) to these patients approximately 6 months after purchasing the lenses.
- DESIGN
This is a single-arm clinical trial. We will carry out two types of study: a prospective (forward) study recruiting patients at BWCH and also a retrospective (backwards) study collecting those patients seen at the ABC between 2008 and 2017. In both studies, data analysis will take place at Aston University after being pseudonymized.
- METHODS
5.1. Recruitment
Prospective study (BWCH, Aston University):
Patients (either males or females) from 5 to 18 years with suspected or confirmed diagnosis of generalised epilepsy with photosensitivity or photosensitive epilepsy (PSE) who are referred to the Neurophysiology Service at BCH for an EEG with IPS/pattern stimulation to confirm the diagnosis or check evolution, whether they are taking AEDs or not. Participants will be able to maintain concentration during the procedure, follow simple commands given by the NHS PI and have the capacity to assent (under 16 years) or consent (16-18 years) to participate after checking that they have understood the purpose of the study.
Retrospective study (Aston University):
•Selection criteria followed in the retrospective study conducted at the ABC were the same, except for the age criterion, since adult patients were also seen at the ABC.
5.2. Trial Procedures
Prospective study (BWCH, Aston University):
- On the first visit to the BWCH, a standardised procedure for EEG with IPS (Kasteleijn-Nolst Trenité et al., 2012) will be performed, followed by stimulation with visual patterns (stationary vertical grids at different spatial frequencies on a screen). If PPRs are shown in response to IPS/pattern stimulation, lenses will be tested to evaluate the relative reduction produced by our lenses \& Z1 on the PPRs evoked by IPS/pattern testing. This reduction will be determined by the change in both the type of PPR and the standardized photoparoxysmal response range (SPR).
- If our lenses are effective and patients/families decide to acquire one of them, they will be asked to fill in a Likert-scale PSQ approximately 6 months after purchasing the lenses. This information will provide us with some feedback on the overall adherence to treatment, tolerability and improvement in the quality of life.
5.2.2) Retrospective study (Aston University): it will consist in the same procedures as the prospective study, but in this case the PSQ was not sent to patients/families.
- DATA ANALYSIS
A minimum sample size of 76 patients was obtained based upon data collected from a previous pilot study, taking into consideration a power value of 80%, an alpha value of 5% and a non-inferiority margin of 0.03.
For each patient, we will compare the reduction/suppression on both the PPR and the SPR between the different lenses (α=0.05). PSQ results will be expressed by the percentages of patients/parents who marked a particular response in these multiple-choice questionnaires.
Missed data (patients who finally drop out of the study) will not be considered for analysis purposes.
- ETHICAL CONSIDERATIONS
All procedures conducted will comply with the Declaration of Helsinki as revised in 2013, the Data Protection Act 1998 and Local Information Governance protocols. Consent will be sought from parents/legal guardians and patients over 15 years, as well as assent in the case of younger patients.
Only pseudonymized raw data will be available for sharing outside of the department as the analysis is to be performed by the PI-based at the sponsor site (Aston University). Data storage will be in keeping with the Trust Information Governance policies.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Participants will be recruited among those patients (both males and females) from 5 to 18 years with suspected or confirmed diagnosis of generalised epilepsy with photosensitivity or photosensitive epilepsy (PSE) who comply with the established inclusion criteria. No control patients will be required, since each patient will be tested with the different lenses in a specific order and will be, in turn, his/her own control. No randomisation will be carried out in our study.
| Arm | Type | Receives |
|---|---|---|
| 5 Lenses | Experimental | Device: Z1 lens, Device: Experimental Lens 1, Device: Experimental Lens 2, Device: Experimental Lens 3, Device: Experimental Lens 4The five lenses will be tested in each patient following always the same specific order, with the most protective lenses tested first (Z1). Z1F133 (Zeiss Clarlet Z1) is a CE marked device manufactured by Carl Zeiss Vision International GmBH (Aalen, Germany). Our lenses are CE marked devices manufactured by Cerium Optical Products (Kent, UK). |
Who may qualify
- Ages
- 5 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Z1 lensAlso: Zeiss F133CE marked device | Device | 5 Lenses |
| Experimental Lens 1CE marked device | Device | 5 Lenses |
| Experimental Lens 2CE marked device | Device | 5 Lenses |
| Experimental Lens 3CE marked device | Device | 5 Lenses |
| Experimental Lens 4CE marked device | Device | 5 Lenses |
Primary outcome
PPR change
Time frame: Baseline (First visit T0)
Relative change in the photoparoxysmal response grade
SPR change
Time frame: Baseline (First visit T0)
Relative change in the standardized photoparoxysmal response range (SPR)
1 secondary outcome
Adherence and tolerability to lenses in everyday life
Time frame: 6 months after acquiring the lenses (T6)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2024.
- Background: PubMed 10541598Capovilla G, Beccaria F, Romeo A, Veggiotti P, Canger R, Paladin F. Effectiveness of a particular blue lens on photoparoxysmal response in photosensitive epileptic patients. Ital J Neurol Sci. 1999 Jun;20(3):161-6. doi: 10.1007/s100720050026.
- Background: PubMed 16529617Capovilla G, Gambardella A, Rubboli G, Beccaria F, Montagnini A, Aguglia U, Canevini MP, Casellato S, Granata T, Paladin F, Romeo A, Stranci G, Tinuper P, Veggiotti P, Avanzini G, Tassinari CA. Suppressive efficacy by a commercially available blue lens on PPR in 610 photosensitive epilepsy patients. Epilepsia. 2006 Mar;47(3):529-33. doi: 10.1111/j.1528-1167.2006.00463.x.
- Background: PubMed 16146439Fisher RS, Harding G, Erba G, Barkley GL, Wilkins A; Epilepsy Foundation of America Working Group. Photic- and pattern-induced seizures: a review for the Epilepsy Foundation of America Working Group. Epilepsia. 2005 Sep;46(9):1426-41. doi: 10.1111/j.1528-1167.2005.31405.x.
- Background: PubMed 14706039Guerrini R, Genton P. Epileptic syndromes and visually induced seizures. Epilepsia. 2004;45 Suppl 1:14-8. doi: 10.1111/j.0013-9580.2004.451011.x.
- BackgroundHarding, G., & Jeavons, P. (1994). Photosensitive Epilepsy: Clinics in Developmental Medicine. London, UK: McKeith Press.
- Background: PubMed 22091642Kasteleijn-Nolst Trenite D, Rubboli G, Hirsch E, Martins da Silva A, Seri S, Wilkins A, Parra J, Covanis A, Elia M, Capovilla G, Stephani U, Harding G. Methodology of photic stimulation revisited: updated European algorithm for visual stimulation in the EEG laboratory. Epilepsia. 2012 Jan;53(1):16-24. doi: 10.1111/j.1528-1167.2011.03319.x. Epub 2011 Nov 16.
- Background: PubMed 16714268Mainster MA. Violet and blue light blocking intraocular lenses: photoprotection versus photoreception. Br J Ophthalmol. 2006 Jun;90(6):784-92. doi: 10.1136/bjo.2005.086553.
- Background: PubMed 8529557Quirk JA, Fish DR, Smith SJ, Sander JW, Shorvon SD, Allen PJ. Incidence of photosensitive epilepsy: a prospective national study. Electroencephalogr Clin Neurophysiol. 1995 Oct;95(4):260-7. doi: 10.1016/0013-4694(95)00118-i.
- Background: PubMed 23891468Verrotti A, Grosso S, D'Egidio C, Parisi P, Spalice A, Pavone P, Capovilla G, Agostinelli S. Valproate in adolescents with photosensitive epilepsy with generalized tonic-clonic seizures only. Eur J Paediatr Neurol. 2014 Jan;18(1):13-8. doi: 10.1016/j.ejpn.2013.06.006. Epub 2013 Jul 26.
- Background: PubMed 10986003Yalcin AD, Kaymaz A, Forta H. Reflex occipital lobe epilepsy. Seizure. 2000 Sep;9(6):436-41. doi: 10.1053/seiz.2000.0424.
- Individual participant dataSharing planned: No. All data recruited at BCH and at the ABC will be pseudonymized before being shared with the PI at Aston University to protect patient confidentiality.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bryony Carr, BSc principal investigator
Birmingham Women's and Children's NHS Foundation Trust
Ana Checa-Ros, MD, PhD principal investigator
Aston University, Birmingham, UK
Sukhvir Wright, MD, PhD study chair
Aston University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Z1 lens, Experimental Lens 1 and Experimental Lens 2 in people with Reflex Epilepsy, Photosensitive and Eyeglasses, run by Aston University at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PPR change (time frame: Baseline (First visit T0)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04076410, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2024.